Overview
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Associated Conditions
- Advanced Ovarian Cancer
- Ovarian Cancer Metastatic
- Advanced Bladder cancer
- Advanced Testicular cancer
- Metastatic Testicular cancer
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/29 | Not Applicable | Not yet recruiting | |||
2025/06/26 | Phase 2 | Not yet recruiting | Ming-Yu Lien | ||
2025/06/18 | Phase 3 | Not yet recruiting | |||
2025/06/17 | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | ||
2025/06/05 | Phase 2 | Recruiting | TJ Biopharma Co., Ltd. | ||
2025/06/03 | Phase 2 | Not yet recruiting | |||
2025/05/30 | Phase 1 | Recruiting | |||
2025/05/14 | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | ||
2025/05/14 | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | ||
2025/05/07 | Phase 3 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| FOSUN PHARMA USA INC | 72266-253 | INTRAVENOUS | 1 mg in 1 mL | 8/4/2023 | |
| Apotex Corp. | 60505-6277 | INTRAVENOUS | 50 mg in 50 mL | 12/21/2023 | |
| Gland Pharma Limited | 68083-163 | INTRAVENOUS | 1 mg in 1 mL | 9/26/2023 | |
| WG Critical Care, LLC | 44567-509 | INTRAVENOUS | 1 mg in 1 mL | 9/16/2021 | |
| Teva Parenteral Medicines, Inc. | 0703-5747 | INTRAVENOUS | 50 mg in 50 mL | 8/30/2022 | |
| Gland Pharma Limited | 68083-162 | INTRAVENOUS | 1 mg in 1 mL | 9/26/2023 | |
| Sagent Pharmaceuticals | 25021-253 | INTRAVENOUS | 1 mg in 1 mL | 6/29/2023 | |
| WG Critical Care, LLC | 44567-511 | INTRAVENOUS | 1 mg in 1 mL | 9/16/2021 | |
| BluePoint Laboratories | 68001-608 | INTRAVENOUS | 1 mg in 1 mL | 12/18/2023 | |
| BluePoint Laboratories | 68001-609 | INTRAVENOUS | 1 mg in 1 mL | 12/18/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| DBL CISPLATIN INJECTION 1 mg/ml | SIN00762P | INJECTION | 1 mg/ml | 5/4/1988 | |
| CISPLATIN INJECTION 1 mg/ml | SIN05418P | INJECTION | 1 mg/ml | 2/18/1991 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Cisplatin Injection | 国药准字H20030675 | 化学药品 | 注射剂 | 7/22/2020 | |
| Cisplatin Injection | 国药准字H53021740 | 化学药品 | 注射剂 | 6/30/2020 | |
| Cisplatin Injection | 国药准字H20043888 | 化学药品 | 注射剂 | 8/4/2020 | |
| Cisplatin Injection | 国药准字H20040813 | 化学药品 | 注射剂 | 6/30/2020 | |
| Cisplatin Injection | 国药准字H20183341 | 化学药品 | 注射剂 | 6/14/2023 | |
| Cisplatin Injection | 国药准字H20043889 | 化学药品 | 注射剂 | 8/4/2020 | |
| Cisplatin Injection | 国药准字H20213819 | 化学药品 | 注射剂 | 10/26/2021 | |
| Cisplatin Injection | 国药准字H53021741 | 化学药品 | 注射剂 | 6/30/2020 | |
| Cisplatin for Injection | 国药准字H37021357 | 化学药品 | 注射剂(无菌分装粉针剂) | 4/20/2020 | |
| Cisplatin for Injection | 国药准字H21020213 | 化学药品 | 注射剂 | 7/23/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| SINPLATIN CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/10ML | N/A | teva pharmaceutical hong kong o/b teva pharmaceutical hong kong limited | N/A | N/A | 8/25/2011 |
| SINPLATIN CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/50ML | N/A | teva pharmaceutical hong kong o/b teva pharmaceutical hong kong limited | N/A | N/A | 8/18/2011 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| DBL CISPLATIN 50mg/50mL Injection | 47275 | Medicine | A | 1/31/1994 | |
| Hospira Cisplatin 50mg/50ml Concentrate for Infusion vial | 159984 | Medicine | A | 3/10/2009 | |
| Cisplatin Injection 50 mg/50 mL (9) | 407210 | Medicine | A | 4/3/2023 | |
| DBL CISPLATIN 100mg/100mL Injection | 47276 | Medicine | A | 1/31/1994 | |
| Cisplatin Injection 100 mg/100 mL (1) | 283858 | Medicine | A | 12/20/2016 | |
| Cisplatin Injection 10 mg/10 mL (10) | 406414 | Medicine | A | 3/20/2023 | |
| Cisplatin Injection 100 mg/100 mL (3) | 407211 | Medicine | A | 4/3/2023 | |
| Hospira Cisplatin Injection 1 mg/mL, 50 mg/50 mL Onco-Tain vial | 462455 | Medicine | A | 9/20/2024 | |
| Hospira DBL Cisplatin Injection 50 mg in 50 mL vial | 374895 | Medicine | A | 9/20/2021 | |
| Cisplatin Sterile Concentrate Injection 50 mg/50 mL oncotain | 138860 | Medicine | A | 5/18/2007 |